Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication.
Six patients with chronic hepatitis B virus (HBV)-induced liver disease were treated with human lymphoblastoid interferon. Daily, alternate day or thrice weekly regimens were employed in two, one and three patients respectively. Thrice weekly intra-muscular injections of 7.5 to 10 megaunits of interferon/m2 appeared to be as effective as daily injections in producing inhibition of HBV replication, were associated with fewer side effects and could be continued for up to 3 months. The effectiveness of this regimen in producing long-term inhibition of viral replication must now be determined.
D000328:Adult; D002648:Child; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy; D006515:Hepatitis B virus / Q000502:physiology*; D006521:Hepatitis, Chronic / Q000188:drug therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014779:Virus Replication / Q000187:drug effects*
D007370:Interferon Type I